APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)

### APBMT 2024丨Global Breakthrough of Chinese CAR-T Therapy: New Advances in the Treatment of Central Nervous System Lymphoma (CNSL)

CNSL

#CAR-T #CNSL #ASCT #APBMT2024 #CARTtherapy #CentralNervousSystemLymphoma #Lymphoma #RRCNSL #APBMT

In the treatment of relapsed or refractory central nervous system lymphoma (R/R CNSL), Chinese CAR-T therapy is pioneering new directions worldwide. Conventional treatments for this disease have shown limited effectiveness, particularly when autologous stem cell transplantation (ASCT) fails, leaving patients facing the dual challenges of relapse and drug resistance. However, recent research from a team of Chinese medical experts has demonstrated that CAR-T therapy shows remarkable efficacy in patients with R/R CNSL, bringing hope to the global fight against central nervous system tumors.

### CAR-T Therapy for ASCT-Failed Patients: Breakthroughs in Safety and Efficacy

At the 29th Annual Congress of the Asia-Pacific Blood and Marrow Transplantation Group (APBMT 2024), a team of Chinese medical experts shared their research results. CAR-T therapy was administered to 11 patients with R/R CNSL who had previously failed ASCT. By using individualized chemotherapy regimens to reduce tumor burden as a bridge to CAR-T therapy, they achieved a 3-month objective response rate (ORR) of 100%, and a 1-year progression-free survival (PFS) rate close to 90%. Most notably, in terms of safety, no patients experienced grade 3 or higher cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS), making the treatment more manageable.

### Facing Challenges and Exploring Future Directions

Although ASCT has been regarded as a consolidative treatment strategy for CNSL, some patients still relapse post-transplant and develop resistance to chemotherapy. Dr. Hu Kai’s team’s research shows that CAR-T therapy remains highly effective and safe for ASCT-failed CNSL patients, offering new hope for patients with chemotherapy resistance. However, to further optimize CAR-T applications, the Chinese medical team continues to explore more individualized approaches, particularly in areas such as timing of treatment, reducing intracranial tumor burden, and improving overall efficacy.

### Research Data Supporting the Efficacy of Chinese CAR-T Therapy

The study included 11 patients with an average age of 58, all of whom had parenchymal brain involvement and received CAR-T therapy following ASCT failure. Post-treatment data further confirmed the efficacy and safety of Chinese CAR-T therapy: the 3-month complete remission rate (CRR) was 100%, and the 1-year PFS rate reached 87.5%. By combining tumor-reducing chemotherapy with CAR-T cell therapy, the Chinese medical team successfully extended patients’ progression-free survival time and overall survival, highlighting the tremendous potential of Chinese CAR-T therapy in treating R/R CNSL.

### Conclusion

This innovative study showcases China’s cutting-edge advancements in CAR-T therapy, especially in high-risk CNSL patients. The efforts of the Chinese medical team not only provide better treatment options for CNSL patients globally but also demonstrate China’s leadership in the global CAR-T research arena.

🎉🎉To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

WhatsApp: Https://wa.me/+8613717959070

Email: doctor.huang@globecancer.com

#CancerTreatment #ChinaMedicalResearch #Immunotherapy #OncologyBreakthrough